NeuroVive Pharmaceutical AB Interim Report January – March 2019

First subjects enrolled in the KL1333 study

Important events January-March 2019

  • NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study.
  • NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds.
  • NeuroVive receives SEK 28.2 Million in a directed new share issue.
  • NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds.

Important events after the reporting period

  • The Supreme Court had delivered its ruling concerning arbitration between NeuroVive and CicloMulsion AG. NeuroVive appealed to the Supreme Court on certain points. The Supreme Court has rejected the appeal.
  • The US Food and Drug Administration, FDA, has approved NeuroVive’s IND (Investigational New Drug) application, enabling clinical studies in the US with the company’s drug candidate NeuroSTAT.

Financial information January-March 2019

  • Net revenues: KSEK 0 (0)
  • Other operating income: KSEK 0 (174)
  • Loss before tax: KSEK -13,822 (-13,053)
  • Loss per share:SEK -0,12 (-0,25)
  • Diluted loss per share:** SEK -0,12 (-0,25)

* Profit/loss for the period divided by average number of shares before dilution at the end of the period.
** Profit/loss for the period divided by average number of shares after dilution at the end of the period.

Please find the complete interim report attached below, or through our website

The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CEST on 21 May 2019.

For more information, please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21,

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard),
For news subscription, please visit  
Follow us on LinkedIn

About NeuroVive 
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for genetic mitochondrial diseases and one project in preparation for a clinical phase II efficacy study for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). The R&D portfolio also consists of projects for genetic mitochondrial disorders, NASH and cancer. The company advances drugs for rare diseases through clinical development into the market, with or without partners. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).